This research study aimed to understand the functional consequences of paraprotein production in patients with Monoclonal Gammopathy of Unknown Significance (MGUS)
In 2019, Unravel MGUS completed the recruitment of participants into the study across nine NHS sites. A total of 664 participants were recruited with an age range spanning 28-92 years. All blood samples provided by the participants were analysed and a survey of the clinical information in the lifestyle questionnaire performed. Unravel MGUS completed the survey with analysis of the two-year follow-up data in May 2021. The findings of this final analysis have provided an insight into the factors that contribute to the progression of MGUS to multiple myeloma. In addition, the study has provided a data-rich resource for further research into MGUS, conversion to multiple myeloma and other unrelated conditions.
Further information can be found on the clinicaltrials.gov website.
The Unravel MGUS team would like to thank all the volunteers and their families for their support and participation.
Unravel MGUS was sponsored by Human Antibody Factory Limited, a Cambridge based drug discovery company.
